Gilead Sciences, Inc. (GILD) is listed on NasdaqGS in the Healthcare sector Β· Drug Manufacturers - General industry. The current price is 150.09, up 0.32% from the previous close. Market cap is approximately $185.9B.
The commentary below is auto-generated by comparing market data (P/E, ROE, D/E, etc.) against predefined thresholds. No LLM is used. This is not a buy/sell recommendation from us or any analyst. For reference only.
GILD's ROE at -20.68% lags the market. ROE stuck below 5% for 1-2 years can be a value trap signal β verify the fundamental story before assuming recovery.
GILD's D/E at 223.47 is on the high side. Credit rating, debt maturity ladder, and refinancing risk all become first-order considerations.
Gilead Sciences, Inc.'s 10.20% revenue growth signals strong momentum. The quality (price vs volume, new vs existing customers) determines whether it is sustainable.
Gilead Sciences, Inc.'s 2.25% yield is standard. If the company is also buying back stock, evaluate on total shareholder return (dividends + buybacks) rather than yield alone.
Pharma and biotech are typically valued through risk-adjusted NPV/DCF on the pipeline.
Gilead Sciences, Inc. is near its 52-week high (157.29), in the top 15% of the range. Prices close to new highs invite two readings β little overhead supply, or stretched expectations β and volume is the usual tiebreaker.
Your watchlist and portfolio, one tap from your home screen β the Margin Call app
The stock moved within a 1.61% high-to-low band on the day, closing 0.32%. That falls within a typical intraday range.
Gilead Sciences, Inc. (GILD) is listed on NasdaqGS, with recent volume of 1,202,603 shares. Volume is a supporting gauge of how much conviction sits behind a price move β the same gain reads differently on heavy versus light turnover.